Your session is about to expire
← Back to Search
Deep neuromuscular blockade (MNB) for Vocal Cord Resection
Phase 1
Waitlist Available
Led By Thomas Schricker, M.D., PhD.
Research Sponsored by Thomas Schricker
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the stay in the operation room, an average of 60 minutes
Awards & highlights
Summary
This trial will help researchers understand if deep neuromuscular blockade provides better surgical conditions for patients who need jet ventilation during vocal cord resection.
Eligible Conditions
- Vocal Cord Resection
- High Frequency Jet Ventilation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during the stay in the operation room, an average of 60 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the stay in the operation room, an average of 60 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Five-point surgical rating scale (SRS)
Secondary outcome measures
Arterial blood pressure
Body temperature
Drug dosages
+9 moreTrial Design
2Treatment groups
Active Control
Group I: Deep neuromuscular blockade (MNB)Active Control2 Interventions
The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Group II: Moderate neuromuscular blockade (MNB)Active Control2 Interventions
The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Find a Location
Who is running the clinical trial?
Thomas SchrickerLead Sponsor
Merck Sharp & Dohme LLCIndustry Sponsor
3,919 Previous Clinical Trials
5,068,251 Total Patients Enrolled
Thomas Schricker, M.D., PhD.Principal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Share this study with friends
Copy Link
Messenger